ClinVar Miner

Submissions for variant NM_003119.4(SPG7):c.2096dup (p.Met699fs)

gnomAD frequency: 0.00004  dbSNP: rs747503698
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000460135 SCV000552956 pathogenic Hereditary spastic paraplegia 7 2023-11-24 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Met699Ilefs*4) in the SPG7 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG7 are known to be pathogenic (PMID: 21623769, 22964162). This variant is present in population databases (rs747503698, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with SPG7-related conditions. ClinVar contains an entry for this variant (Variation ID: 411678). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000489898 SCV000577548 pathogenic not provided 2022-08-12 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 34758253, 33726816)
Athena Diagnostics RCV000489898 SCV000844100 pathogenic not provided 2018-05-30 criteria provided, single submitter clinical testing This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity ( This variant has been identified in at least one individual with clinical features associated with this gene.
Illumina Laboratory Services, Illumina RCV000460135 SCV000914745 uncertain significance Hereditary spastic paraplegia 7 2018-10-11 criteria provided, single submitter clinical testing This variant results in a frameshift and is predicted to result in premature termination of the protein. It was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018) and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score for this variant, it could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene and cDNA change, and amino acid change. No publications were found based on this search. Due to the potential impact of frameshift variants and the lack of clarifying evidence, this variant is classified as a variant of unknown significance but suspicious for pathogenicity for this disease.
Mayo Clinic Laboratories, Mayo Clinic RCV000489898 SCV001715176 pathogenic not provided 2020-12-09 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV003902651 SCV004724679 likely pathogenic SPG7-related disorder 2024-01-29 criteria provided, single submitter clinical testing The SPG7 c.2096dupT variant is predicted to result in a frameshift and premature protein termination (p.Met699Ilefs*4). This variant has been reported in the literature; however, phenotypes of the individuals carrying this variant were not specified (Stranneheim et al. 2021. PubMed ID: 33726816; 100,000 Genomes Project Pilot Investigators et al. 2021. PubMed ID: 34758253). This variant is reported in 0.0095% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in SPG7 are expected to be pathogenic. This variant is interpreted as likely pathogenic.
Genomics England Pilot Project, Genomics England RCV000460135 SCV001760393 pathogenic Hereditary spastic paraplegia 7 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.